Cambridge Heart to Exhibit, Sponsor SCA Prevention Talk at MedAxiom Conference on September 24, 2009

• Press Release
• Source: Cambridge Heart, Inc.
• On 10:48 am EDT, Tuesday September 22, 2009

TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB-CAMH) will exhibit its HearTwave II system and sponsor a medical education talk on sudden cardiac arrest (SCA) prevention at the Fall 2009 MedAxiom Conference.

Related Quotes

Symbol	Price	Change
CAMH.OB	0.08	+0.01

{"s" : "camh.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The conference will be held from September 23 to 25 in Monarch Beach, California. The exhibit will feature the HearTwave II, Cambridge Heart’s flagship diagnostic system capable of performing both stress and MTWA testing.

The talk by Dr. Theodore Chow will take place on Thursday September 24. Dr. Chow, a leading electrophysiologist, is President and Founder of the Silicon Valley Institute for Cardiac Arrest Prevention in San Jose, California.

“Dr. Chow is a nationally recognized expert in the field of risk stratification for sudden cardiac arrest,” said Ali Haghighi-Mood, Cambridge Heart President and CEO. “His insights on SCA prevention can help primary care doctors, cardiologists and other specialists avert what has long been a major cause of death in the US.”

Before founding the Silicon Valley Institute for Cardiac Arrest Prevention earlier this year, Dr. Chow was a partner and Director of Electrophysiology at the Ohio Heart and Vascular Center in Cincinnati. He has published several studies on MTWA and risk stratification for SCA.

About MedAxiom

MedAxiom is a service and information provider to an alliance of 300 cardiology practices and 5,400 cardiologists nationwide, based in Neptune Beach, Florida.

www.medaxiom.com

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company’s products incorporate proprietary Microvolt T-Wave Alternans™ measurement technologies, including the patented Analytic Spectral Method^® and ultrasensitive disposable electrode sensors. The Company’s MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.

Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.

http://www.cambridgeheart.com.

Statements contained in this press release are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as “believes”, “expects”, “anticipates”, “plans”, “estimates”, “could”, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to achieve broad market acceptance of the Company’s MTWA technology, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company's target markets, failure to obtain or maintain adequate levels of first-party reimbursement for use of the Company's MTWA test, customer delays in making final buying decisions, decreased demand for the Company's products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology and other factors identified in our most recent Annual Report on Form 10-K under “Risk Factors”, which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.

At Cambridge Heart:
Vincenzo LiCausi, 978-654-7600 x 6645
Chief Financial Officer
vincenzol@cambridgeheart.com
or
Media:
KOGS Communication
Edna Kaplan, 781-639-1910
kaplan@kogspr.com
or
Investor Relations:
Allen & Caron
Matt H. Clawson, 949-474-4300
matt@allencaron.com